Related Experiment Videos
Clinical evaluation of netilmicin therapy in serious infections
Abstract:
Netilmicin, a new semisynthetic aminoglycoside, was evaluated in the therapy of 33 episodes of infection in 30 patients. Eighteen patients had documented bacteremia. Infection sites included pulmonary, urinary tract and soft tissue areas. A complete bacteriologic and clinical cure rate of 85 per cent was achieved. No treatment failures occurred in the bacteremic group. Although netilmicin is less effective than gentamicin in vitro against Pseudomonas, it was clinically and bacteriologically effective. Netilmicin bacteriologic cures occurred in patients whose organisms were inhibited by 6.2 microgram/ml or less of netilmicin. Despite a uniform dosing protocol, a wide range of netilmicin serum levels was obtained. Adverse effects were limited to one case of transient nephrotoxicity and one Candida urinary suprainfection. Netilmicin appears to be an effective, safe agent for the therapy of serious infections.
Insights
Netilmicin, a new semisynthetic aminoglycoside, demonstrated an 85% cure rate in serious infections, including bacteremia. This effective and safe antibiotic shows promise for treating various infections.
Area of Science:
- Pharmacology
- Infectious Diseases
- Clinical Microbiology
Background:
- Aminoglycosides are crucial in treating severe bacterial infections.
- The emergence of antibiotic resistance necessitates novel therapeutic agents.
- Netilmicin is a semisynthetic aminoglycoside with a broad spectrum of activity.
Purpose of the Study:
- To evaluate the efficacy and safety of netilmicin in treating serious infections.
- To assess the clinical and bacteriologic outcomes of netilmicin therapy.
- To compare netilmicin's in vitro activity with gentamicin against Pseudomonas.
Main Methods:
- A clinical trial involving 30 patients with 33 episodes of infection.
- Infections included pulmonary, urinary tract, and soft tissue sites, with 18 cases of bacteremia.
- Serum levels of netilmicin were monitored under a uniform dosing protocol.
Main Results:
- An 85% complete bacteriologic and clinical cure rate was achieved.
- No treatment failures were observed in patients with bacteremia.
- Netilmicin demonstrated clinical efficacy even against Pseudomonas, despite lower in vitro activity compared to gentamicin.
- Bacteriologic cures were associated with netilmicin inhibition of 6.2 microgram/ml or less.
- Adverse effects were minimal, including transient nephrotoxicity and a Candida urinary suprainfection.
Conclusions:
- Netilmicin is an effective and safe therapeutic agent for serious infections.
- It offers a viable treatment option, particularly in cases of bacteremia.
- Further research may explore optimizing dosing to achieve consistent serum levels.